Mississippi Veterans PTSD Ibogaine Research Pilot Program; create.

S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~ G1/2
26/SS26/R1048.1
PAGE 1 (ens\tb)

To: Public Health and
Welfare
MISSISSIPPI LEGISLATURE REGULAR SESSION 2026

By: Senator(s) Tate

SENATE BILL NO. 2562

AN ACT TO CREATE THE MISSISSIPPI VETERANS PTSD IBOGAINE 1
RESEARCH PILOT PROGRAM WITHIN THE STATE DEPARTMENT OF HEALTH TO 2
SUPPORT LAWFUL CLINICAL RESEARCH INVOLVING IBOGAINE WITH VOLUNTEER 3
MISSISSIPPI VETERANS DIAGNOSED WITH PTSD, SUBJECT TO STRICT 4
SAFEGUARDS AND FULL COMPLIANCE WITH APPLICABLE STATE AND FEDERAL 5
LAW; TO REQUIRE THE STATE DEPARTMENT OF HEALTH TO ADOPT AND 6
DEVELOP A RESEARCH PROTOCOL; TO PROVIDE ELIGIBILITY REQUIREMENTS 7
FOR PARTICIPANTS; TO REQUIRE THE STATE DEPARTMENT OF HEALTH TO 8
PROVIDE AN ANNUAL REPORT TO THE LEGISLATURE; TO PROVIDE THAT THIS 9
SECTION SHALL REPEAL BY OPERATION OF LAW ON JULY 1, 2028; TO AMEND 10
SECTIONS 41-29-113 AND 41-29-115, MISSISSIPPI CODE OF 1972, TO 11
RESCHEDULE IBOGAINE FROM SCHEDULE I TO SCHEDULE II OF THE UNIFORM 12
CONTROLLED SUBSTANCES ACT; AND FOR RELATED PURPOSES. 13
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI: 14
SECTION 1. (1) The Legislature finds that post-traumatic 15
stress disorder among Mississippi veterans is a significant public 16
health concern and that controlled, ethically approved clinical 17
research is necessary to evaluate investigational interventions. 18
The purpose of this section is to authorize a pilot program to 19
support lawful clinical research involving ibogaine with volunteer 20
Mississippi veterans diagnosed with PTSD, subject to strict 21
safeguards and full compliance with applicable state and federal 22
law. 23
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 2 (ens\tb)

(2) As used in this section, the following terms have the 24
meaning ascribed herein unless the context requires otherwise: 25
(a) "Department" means the State Department of Health; 26
(b) "Ibogaine" means the controlled substance regulated 27
under Section 41-29-115(f)(3). 28
(c) "Program" means the Mississippi Veterans PTSD 29
Ibogaine Research Pilot Program established in subsection (3) of 30
this section. 31
(3) The Mississippi Veterans PTSD Ibogaine Research Pilot 32
Program is hereby created in the State Department of Health. 33
Subject to appropriation by the Legislature, the department 34
administer the program. The department may consult with the 35
Department of Mental Health and the State Veterans Affairs Board 36
in the administration of the program. The department shall 37
develop and adopt a research protocol for the program. 38
(4) (a) The department shall limit participation to 39
individuals who: 40
(i) Are veterans of the United States Armed 41
Forces; 42
(ii) Are residents of the State of Mississippi; 43
(iii) Have a documented diagnosis of PTSD by a 44
licensed physician, psychologist, or other appropriately licensed 45
mental health professional; and 46
(iv) Meet medical screening and inclusion or 47
exclusion criteria established in the approved research protocol. 48
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 3 (ens\tb)

(b) Participation by an individual shall be voluntary 49
without any compensation paid to participants. 50
(5) (a) No ibogaine may be possessed, manufactured, 51
distributed, dispensed, or administered under the program unless 52
done so under a research protocol that has received: 53
(i) Approval by an Institutional Review Board duly 54
constituted under applicable federal law; and 55
(ii) Approval, registration, and licensing 56
required under state and federal law, including any necessary 57
authorization from the United States Food and Drug Administration 58
and registration with the United States Drug Enforcement 59
Administration. 60
(b) All activities under the Program shall be conducted 61
in compliance with the Mississippi Uniform Controlled Substances 62
Law and rules of the appropriate Mississippi licensing boards 63
governing controlled-substance registration for research. 64
(6) (a) Ibogaine obtained or used under this section shall 65
be limited to use within an approved clinical research protocol 66
and may not be prescribed, dispensed, or distributed for routine 67
clinical treatment outside the program. 68
(b) Nothing in this section shall be construed to 69
authorize retail sale of ibogaine or distribution or use of 70
ibogaine outside the research protocol. 71
(7) A qualified research institution, principal 72
investigator, licensed practitioner, research staff member, or 73
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 4 (ens\tb)

program participant acting in accordance with approvals and 74
authorizations required by subsection (5) shall be exempt from 75
state criminal prosecution for possession, administration, 76
dispensing, or distribution of ibogaine to the extent of such 77
authorization. 78
(8) The department shall submit an annual report to the 79
Governor, the Lieutenant Governor, and the Chairs of the Senate 80
and House Committees with jurisdiction over public health. 81
Reports shall include: 82
(a) Number of participants enrolled and completing the 83
protocol; 84
(b) Adverse events and safety outcomes (in aggregate, 85
de-identified form); 86
(c) Outcome measures defined in the protocol (in 87
aggregate, de-identified form); 88
(d) Program costs and funding sources; and 89
(e) Recommendations for continuation, modification, or 90
termination. 91
(9) This section shall stand repealed on July 1, 2028. 92
SECTION 2. Section 41-29-113, Mississippi Code of 1972, is 93
amended as follows: 94
41-29-113. 95
SCHEDULE I 96
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 5 (ens\tb)

(a) Schedule I consists of the drugs and other substances, 97
by whatever official name, common or usual name, chemical name, or 98
brand name designated, that is listed in this section. 99
(b) Opiates. Unless specifically excepted or unless listed 100
in another schedule, any of the following opiates, including their 101
isomers, esters, ethers, salts and salts of isomers, esters and 102
ethers, whenever the existence of these isomers, esters, ethers 103
and salts is possible within the specific chemical designation: 104
(1) Acetyl-alpha-methylfentanyl 105
(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide); 106
(2) Acetylmethadol; 107
(3) Acetyl fentanyl 108
(N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); 109
(4) Acryl fentanyl 110
(N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide), also known as 111
acryloylfentanyl; 112
(5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino) 113
cyclohexylmethyl]benzamide); 114
(6) Allylprodine; 115
(7) Alphacetylmethadol, except levo-alphacetylmethadol 116
(levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM); 117
(8) Alphameprodine; 118
(9) Alphamethadol; 119
(10) Alpha′-methyl butyryl fentanyl 120
(2-methyl-N-1-phenethylpiperidin-4-yl)-N-phenylbutanamide); 121
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 6 (ens\tb)

(11) Alpha-Methylfentanyl 122
(N-[1-alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide; 123
1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine); 124
(12) Alpha-Methylthiofentanyl 125
(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide126
); 127
(13) Benzethidine; 128
(14) Betacetylmethadol; 129
(15) Beta-Hydroxyfentanyl 130
(N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide); 131
(16) Beta-Hydroxy-3-methylfentanyl 132
(N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenylpr133
opanamide); 134
(17) Beta-Hydroxythiofentanyl 135
(N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpr136
opionamide); 137
(18) Betameprodine; 138
(19) Betamethadol; 139
(20) Beta-Methyl fentanyl 140
(N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide), also 141
known as β-methyl fentanyl; 142
(21) Beta'-Phenyl fentanyl 143
(N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide), also 144
known as β'-phenyl fentanyl or 3-phenylpropanoyl fentanyl; 145
(22) Betaprodine; 146
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 7 (ens\tb)

(23) Brorphine (1–(1–(1–147
(4-bromophenyl)ethyl)piperidin-4–yl)–148
1,3-dihydro-2H-benzo[d]imidazol-2-one); 149
(24) Butyrl fentanyl 150
(N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide); 151
(25) Clonitazene; 152
(26) Crotonyl fentanyl 153
((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide); 154
(27) Cyclopentyl fentanyl 155
(N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide); 156
(28) Cyclopropyl fentanyl 157
(N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide); 158
(29) Dextromoramide; 159
(30) Diampromide; 160
(31) Diethylthiambutene; 161
(32) Difenoxin; 162
(33) Dimenoxadol; 163
(34) Dimepheptanol; 164
(35) 2′,5′-dimethoxyfentanyl 165
(N-1-2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide); 166
(36) Dimethylthiambutene; 167
(37) Dioxaphetyl butyrate; 168
(38) Dipipanone; 169
(39) Ethylmethylthiambutene; 170
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 8 (ens\tb)

(40) Etodesnitazene 171
(2-2-4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amin172
e, also known as etazene; 173
(41) Etonitazene; 174
(42) Etoxeridine; 175
(43) Fentanyl carbamate 176
(ethyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate); 177
(44) Fentanyl-related substances, meaning any substance 178
not otherwise listed under another schedule and for which no 179
exemption or approval is in effect under Section 505 of the 180
Federal Food, Drug, and Cosmetic Act [21 USC 355] that is 181
structurally related to fentanyl by one or more of the following 182
modifications: 183
(A) Replacement of the phenyl portion of the 184
phenethyl group by any monocycle, whether or not further 185
substituted in or on the monocycle; 186
(B) Substitution in or on the phenethyl group with 187
alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro 188
groups; 189
(C) Substitution in or on the piperidine ring with 190
alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, 191
amino or nitro groups; 192
(D) Replacement of the aniline ring with any 193
aromatic monocycle whether or not further substituted in or on the 194
aromatic monocycle; and/or 195
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 9 (ens\tb)

(E) Replacement of the N-propionyl group by 196
another acyl group. 197
(45) 4-Fluoroisobutyryl fentanyl 198
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide), 199
also known as para-fluoroisobutyryl fentanyl); 200
(46) 2'-Fluoro ortho-fluorofentanyl 201
(N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl) 202
propionamide), also known as 2'-fluoro 2-fluorofentanyl; 203
(47) Furanyl fentanyl 204
(N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide); 205
(48) 3-furanyl fentanyl 206
(N-1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide); 207
(49) Furethidine; 208
(50) Hydroxypethidine; 209
(51) Isobutyryl fentanyl 210
(N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide); 211
(52) Isotonitazene (N,N-diethyl-2-(2-(4 212
isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine); 213
(53) Isovaleryl fentanyl 214
(3-methyl-N-1-phenethylpiperidin-4-yl)-N-phenylbutanamide); 215
(54) Ketobemidone (including the optical and geometric 216
isomers); 217
(55) Levomoramide; 218
(56) Levophenacylmorphan; 219
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 10 (ens\tb)

(57) Meta-fluorofentanyl 220
(N-3-fluorophenyl)-N-1-phenethylpiperidin-4-yl)propionamide); 221
(58) Meta-fluoroisobutyryl fentanyl 222
(N-(3-fluorophenyl)-N-1-phenethylpiperidin-4-yl)isobutyramide); 223
(59) Methoxyacetyl fentanyl 224
(2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); 225
(60) 4'-Methyl acetyl fentanyl 226
(N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide); 227
(61) 2-methyl AP–237 228
(1-2-methyl-4-3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one; 229
(62) 3-Methylfentanyl 230
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide); 231
(63) 3-Methylthiofentanyl (N-[3-methyl-1- 232
(2-thienylethyl)-4-piperidinyl]-N-phenylpropanamide); 233
(64) Para-methoxyfuranyl fentanyl 234
(N-(4-methoxyphenyl)-N-1-phenethylpiperidin-4-yl)furan-2-carboxami235
de); 236
(65) Metonitazene 237
(N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)e238
than-1-amine (metonitazene); 239
(66) Morpheridine; 240
(67) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); 241
(68) MT-45 242
(1-cyclohexyl-4-(1,2-diphenylethyl)piperazine); 243
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 11 (ens\tb)

(69) N-pyrrolidino etonitazene 244
2-4-ethoxybenzyl)-5-nitro-1-2-pyrrolidin-1-yl)ethyl)-1H-benzimidaz245
ole, also known as etonitazepyne; 246
(70) Noracymethadol; 247
(71) Norlevorphanol; 248
(72) Normethadone; 249
(73) Norpipanone; 250
(74) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N- 251
(1-phenethylpiperidin-4-yl)acetamide); 252
(75) Ortho-Fluoroacryl fentanyl 253
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide); 254
(76) Ortho-Fluorobutyryl fentanyl 255
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide), also 256
known as 2-fluorobutyryl fentanyl; 257
(77) Ortho-Fluorofentanyl 258
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide), 259
also known as 2-fluorofentanyl; 260
(78) Ortho-fluorofuranyl fentanyl 261
(N-2-fluorophenyl)-N-1-phenethylpiperidin-4-yl)furan-2-carboxamide262
); 263
(79) Ortho-Fluoroisobutyryl fentanyl 264
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide); 265
(80) Ortho-Methyl acetylfentanyl 266
(N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide), also 267
known as 2-methyl acetylfentanyl; 268
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 12 (ens\tb)

(81) Ortho-Methyl methoxyacetyl fentanyl 269
(2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl) 270
acetamide), also known as 2-methyl methoxyacetyl fentanyl; 271
(82) Para-Chloroisobutyryl fentanyl 272
(N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide); 273
(83) Para-Fluorobutyryl fentanyl 274
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); 275
(84) Para-Fluorofentanyl (N-(4-fluorophenyl) 276
-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide); 277
(85) Para-Fluoro furanyl fentanyl N-(4-fluorophenyl)-N- 278
(1-phenethylpiperidin-4-yl)furan-2-carboxamide); 279
(86) Para-Methoxybutyryl fentanyl 280
(N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); 281
(87) Para-methylcyclopropyl fentanyl 282
(N-4-methylphenyl)-N-1-phenethylpiperidin-4-yl)cyclopropanecarboxa283
mide); 284
(88) Para-Methylfentanyl 285
(N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide), 286
also known as 4-methylfentanyl); 287
(89) PEPAP 288
(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); 289
(90) Phenadoxone; 290
(91) Phenampromide; 291
(92) Phenomorphan; 292
(93) Phenoperidine; 293
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 13 (ens\tb)

(94) Phenyl fentanyl 294
(N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide), also known as 295
benzoyl fentanyl; 296
(95) Piritramide; 297
(96) Proheptazine; 298
(97) Properidine; 299
(98) Propiram; 300
(99) Protonitazene 301
N,N-diethyl-2-5-nitro-2-4-propoxybenzyl)-1H-benzimidazol-1-yl)etha302
n-1-amine; 303
(100) Racemoramide; 304
(101) Tetrahydrofuranyl fentanyl 305
(N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2- 306
carboxamide); 307
(102) Thiofentanyl 308
(N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide); 309
(103) Thiofuranyl fentanyl 310
(N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide), 311
also known as 2-thiofuranyl fentanyl or thiophene fentanyl; 312
(104) Tilidine; 313
(105) Trimeperidine; 314
(106) U-47700, (3,4-dichloro-N- 315
[2-(dimethylamino)cyclohexyl]-N-methylbenzamide); 316
(107) Valeryl fentanyl 317
(N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide). 318
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 14 (ens\tb)

(c) Opium derivatives. Unless specifically excepted or 319
unless listed in another schedule, any of the following opium 320
derivatives, their salts, isomers and salts of isomers, whenever 321
the existence of these salts, isomers and salts of isomers is 322
possible within the specific chemical designation: 323
(1) Acetorphine; 324
(2) Acetyldihydrocodeine; 325
(3) Benzylmorphine; 326
(4) Codeine methylbromide; 327
(5) Codeine-N-Oxide; 328
(6) Cyprenorphine; 329
(7) Desomorphine; 330
(8) Dihydromorphine; 331
(9) Drotebanol; 332
(10) Etorphine (except hydrochloride salt); 333
(11) Heroin; 334
(12) Hydromorphinol; 335
(13) Methyldesorphine; 336
(14) Methyldihydromorphine; 337
(15) Monoacetylmorphine; 338
(16) Morphine methylbromide; 339
(17) Morphine methylsulfonate; 340
(18) Morphine-N-Oxide; 341
(19) Myrophine; 342
(20) Nicocodeine; 343
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 15 (ens\tb)

(21) Nicomorphine; 344
(22) Normorphine; 345
(23) Pholcodine; 346
(24) Thebacon. 347
(d) Hallucinogenic substances. Unless specifically excepted 348
or unless listed in another schedule, any material, compound, 349
mixture or preparation which contains any quantity of the 350
following substances, their salts, isomers (whether optical, 351
positional, or geometric) and salts of isomers, whenever the 352
existence of these salts, isomers and salts of isomers is possible 353
within the specific chemical designation: 354
(1) Alpha-ethyltryptamine; 355
(2) 4-bromo-2,5-dimethoxy-amphetamine; 356
(3) 4-bromo-2,5-dimethoxyphenethylamine; 357
(4) 2,5-dimethoxyamphetamine; 358
(5) 2,5-dimethoxy-4-ethylamphetamine (DOET); 359
(6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine 360
(2C-T-7); 361
(7) 4-methoxyamphetamine; 362
(8) 5-methoxy-3,4-methylenedioxy-amphetamine; 363
(9) 4-methyl-2,5-dimethoxy-amphetamine; 364
(10) 3,4-methylenedioxy amphetamine; 365
(11) 3,4-methylenedioxymethamphetamine (MDMA); 366
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 16 (ens\tb)

(12) 3,4-methylenedioxy-N-ethylamphetamine (also known 367
as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl 368
MDA, MDE, MDEA); 369
(13) N-hydroxy-3,4-methylenedioxyamphetamine (also 370
known as N-hydroxy MDA, N-OHMDA, and 371
N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine); 372
(14) 3,4,5-trimethoxy amphetamine; 373
(15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); 374
(16) Alpha-methyltryptamine (also known as AMT); 375
(17) Bufotenine; 376
(18) Diethyltryptamine; 377
(19) Dimethyltryptamine; 378
(20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); 379
(21) * * * [Deleted]. 380
(22) Lysergic acid diethylamide (LSD); 381
(23) (A) Marijuana (Hemp as defined and regulated 382
under Sections 69-25-201 through 69-25-221 and Cannabidiol 383
contained in a legend drug product approved by the Federal Food 384
and Drug Administration or obtained under Section 41-29-136 are 385
exempt under Schedule I); 386
(B) Hashish; 387
(24) Mescaline; 388
(25) Parahexyl; 389
(26) Peyote; 390
(27) N-ethyl-3-piperidyl benzilate; 391
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 17 (ens\tb)

(28) N-methyl-3-piperidyl benzilate; 392
(29) Psilocybin; 393
(30) Psilocyn; 394
(31) Tetrahydrocannabinols, meaning 395
tetrahydrocannabinols contained in a plant of the genus Cannabis 396
(cannabis plant), as well as the synthetic equivalents of the 397
substances contained in the cannabis plant, or in the resinous 398
extractives of such plant, and/or synthetic substances, 399
derivatives, and their isomers with similar chemical structure and 400
pharmacological activity to those substances contained in the 401
plant such as the following: 402
(A) 1 cis or trans tetrahydrocannabinol; 403
(B) 6 cis or trans tetrahydrocannabinol; 404
(C) 3,4 cis or trans tetrahydrocannabinol. 405
(Since nomenclature of these substances is not 406
internationally standardized, compounds of these structures, 407
regardless of atomic positions, are covered.) 408
("Tetrahydrocannabinols" excludes dronabinol and nabilone.) 409
For purposes of this paragraph, tetrahydrocannabinols do not 410
include hemp or hemp products regulated under Sections 69-25-201 411
through 69-25-221. 412
However, the following products are exempted from control: 413
(i) THC-containing industrial products made 414
from cannabis stalks (e.g., paper, rope and clothing); 415
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 18 (ens\tb)

(ii) Processed cannabis plant materials used 416
for industrial purposes, such as fiber retted from cannabis stalks 417
for use in manufacturing textiles or rope; 418
(iii) Animal feed mixtures that contain 419
sterilized cannabis seeds and other ingredients (not derived from 420
the cannabis plant) in a formula designed, marketed and 421
distributed for nonhuman consumption; 422
(iv) Personal care products that contain oil 423
from sterilized cannabis seeds, such as shampoos, soaps, and body 424
lotions (if the products do not cause THC to enter the human 425
body); 426
(v) Hemp as regulated under Sections 427
69-25-201 through 69-25-221; and 428
(vi) Any product derived from the hemp plant 429
designed for human ingestion and/or consumption that is approved 430
by the United States Food and Drug Administration; 431
(32) Phencyclidine; 432
(33) Ethylamine analog of phencyclidine (PCE); 433
(34) Pyrrolidine analog of phencyclidine (PHP, PCPy); 434
(35) Thiophene analog of phencyclidine; 435
(36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy); 436
(37) 4-methylmethcathinone (mephedrone); 437
(38) 3,4-methylenedioxypyrovalerone (MDPV); 438
(39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E); 439
(40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D); 440
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 19 (ens\tb)

(41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); 441
(42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); 442
or 2,5-dimethoxy-4-iodophenethylamine; 443
(43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine 444
(2C-T-2); 445
(44) 446
2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); 447
(45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H); 448
(46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N); 449
(47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine 450
(2C-P); 451
(48) 3,4-methylenedioxy-N-methylcathinone(methylone); 452
(49) 453
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine 454
(25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36); 455
(50) 456
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine 457
(25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); 458
(51) 459
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or 460
N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; 461
Cimbi-5); 462
(52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1, 463
4-benzodiazepin-2-one (also known as Phenazepam); 464
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 20 (ens\tb)

(53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8, 465
11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene 466
(also known as Etizolam); 467
(54) Salvia divinorum; 468
(55) Synthetic cannabinoids. Unless specifically 469
excepted or unless listed in another schedule, any material, 470
compound, mixture, or preparation which contains any quantity of a 471
synthetic cannabinoid found in any of the following chemical 472
groups, whether or not substituted to any extent, or any of those 473
groups which contain any synthetic cannabinoid salts, isomers, or 474
salts of isomers, whenever the existence of such salts, isomers, 475
or salts of isomers is possible within the specific chemical 476
designation, including all synthetic cannabinoid chemical 477
analogues in such groups: 478
(A) (6aR,10aR)-9-(hydroxymethyl)-6, 479
6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] 480
chromen-1-ol (also known as HU-210 or 481
1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol); 482
(B) Naphthoylindoles and naphthylmethylindoles, 483
being any compound structurally derived from 3-(1-naphthoyl)indole 484
or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted 485
in the indole ring to any extent, or in the naphthyl ring to any 486
extent; 487
(C) Naphthoylpyrroles, being any compound 488
structurally derived from 3-(1-naphthoyl)pyrrole, whether or not 489
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 21 (ens\tb)

substituted in the pyrrole ring to any extent, or in the naphthyl 490
ring to any extent; 491
(D) Naphthylmethylindenes, being any compound 492
structurally derived from 1-(1-naphthylmethyl)indene, whether or 493
not substituted in the indene ring to any extent or in the 494
naphthyl ring to any extent; 495
(E) Phenylacetylindoles, being any compound 496
structurally derived from 3-phenylacetylindole, whether or not 497
substituted in the indole ring to any extent or in the phenyl ring 498
to any extent; 499
(F) Cyclohexylphenols, being any compound 500
structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether 501
or not substituted in the cyclohexyl ring to any extent or in the 502
phenolic ring to any extent; 503
(G) Benzoylindoles, whether or not substituted in 504
the indole ring to any extent or in the phenyl ring to any extent; 505
(H) Adamantoylindoles, whether or not substituted 506
in the indole ring to any extent or in the adamantoyl ring system 507
to any extent; 508
(I) Tetrahydro derivatives of cannabinol and 509
3-alkyl homologues of cannabinol or of its tetrahydro derivatives, 510
except where contained in cannabis or cannabis resin; 511
(J) 3-Cyclopropylmethanone indole or 512
3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by 513
substitution at the nitrogen atom of the indole ring, whether or 514
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 22 (ens\tb)

not further substituted in the indole ring to any extent, whether 515
or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl 516
rings to any extent; 517
(K) Quinolinyl ester indoles, being any compound 518
structurally derived from 1H-indole-3carboxylic acid-8-quinolinyl 519
ester, whether or not substituted in the indole ring to any extent 520
or the quinolone ring to any extent; 521
(L) 3-carboxamide-1H-indazoles, whether or not 522
substituted in the indazole ring to any extent and substituted to 523
any degree on the carboxamide nitrogen and 524
3-carboxamide-1H-indoles, whether or not substituted in the indole 525
ring to any extent and substituted to any degree on the 526
carboxamide nitrogen; 527
(M) Cycloalkanemethanone Indoles, whether or not 528
substituted at the nitrogen atom on the indole ring, whether or 529
not further substituted in the indole ring to any extent, whether 530
or not substituted on the cycloalkane ring to any extent; 531
(56) Naphthalen-1-yl 532
1-(5-fluoropentyl)-1H-indole-3-carboxylate, also known as NM2201 533
or CBL2201; 534
(57) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H- 535
pyrrolo[2,3-b]pyridine-3-carboxamide, also known as 536
5F-CUMYL-P7AICA or SGT-25; 537
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 23 (ens\tb)

(58) Methyl 538
2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutano539
ate, also known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA); 540
(59) 1-(4-methoxyphenyl)-N-methylpropan-2-amine, also 541
known as para-methoxymethamphetamine or PMMA; 542
(60) Ethyl 2-(1-(5-fluoropentyl) 543
-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, also known as 544
5F-EDMB-PINACA; 545
(61) Methyl 546
2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoa547
te, also known as 5F-MDMB-PICA or 5F-MDMB-2201; 548
(62) 549
N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, 550
also known as FUB-AKB48 or FUB-APINACA or AKB48 551
N-(4-fluorobenzyl); 552
(63) 553
(1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)554
methanone, also known as FUB-144; 555
(64) N-ethylhexedrone, also known as 556
α-ethylaminohexanophenone or 2-(ethylamino)-1-phenylhexan-1-one; 557
(65) Alpha-pyrrolidinohexanophenone, also known as 558
α-PHP or α-pyrrolidinohexanophenone or 559
1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one); 560
(66) 4-methyl-alpha-ethylaminopentiophenone, also known 561
as 4-MEAP or 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one); 562
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 24 (ens\tb)

(67) 4'-methyl-alpha-pyrrolidinohexiophenone, also 563
known as MPHP or 4'-methyl-alpha-pyrrolidinohexanophenone or 564
1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one); 565
(68) Alpha-pyrrolidinoheptaphenone (also known as PV8; 566
1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one); 567
(69) 4'-chloro-alpha-pyrrolidinovalerophenone, also 568
known as 4-chloro-α-PVP or 4'-chloro-α-pyrrolidinopentiophenone or 569
1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); 570
(70) 571
2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one, also known as 572
methoxetamine or MXE; 573
(71) Zipeprol 574
(1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylp575
ropan-2-ol); 576
(72) Eutylone 577
(1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one); and 578
(73) ADB–BUTINACA 579
N-1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carb580
oxamide. 581
(e) Depressants. Unless specifically excepted or unless 582
listed in another schedule, any material, compound, mixture, or 583
preparation which contains any quantity of the following 584
substances having a depressant effect on the central nervous 585
system, including their salts, isomers, and salts of isomers, 586
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 25 (ens\tb)

whenever the existence of such salts, isomers, and salts of 587
isomers is possible within the specific chemical designation: 588
(1) Clonazolam, 589
6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]590
benzodiazepine; 591
(2) Flualprazolam, 592
8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4593
]benzodiazepine; 594
(3) Flubromazepam, 595
7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 596
(4) Flubromazolam, 597
8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]598
benzodiazepin; 599
(5) Gamma-hydroxybutyric acid (other names include: 600
GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic 601
acid; sodium oxybate; sodium oxybutyrate); 602
(6) Mecloqualone; 603
(7) Methaqualone. 604
(f) Stimulants. Any material, compound, mixture or 605
preparation which contains any quantity of the following central 606
nervous system stimulants including optical salts, isomers and 607
salts of isomers unless specifically excepted or unless listed in 608
another schedule: 609
(1) Aminorex; 610
(2) Amineptine 611
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 26 (ens\tb)

(7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic 612
acid); 613
(3) N-benzylpiperazine (also known as BZP and 614
1-benzylpiperazine); 615
(4) Cathinone; 616
(5) 4,4'-Dimethylaminorex, also known as 4,4'-DMAR or 617
4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 618
4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine); 619
(6) Fenethylline; 620
(7) Mesocarb 621
(N-phenyl-N' -(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3- 622
ium-5-yl)carbamimidate); 623
(8) Methcathinone; 624
(9) Methiopropamine 625
(N-methyl-1-(thiophen-2-yl)propan-2-amine)); 626
(10) 4-methylaminorex (also known as 627
2-amino-4-methyl-5-phenyl-2-oxazoline); 628
(11) N-ethylamphetamine; 629
(12) Any material, compound, mixture or preparation 630
which contains any quantity of N,N-dimethylamphetamine. (Other 631
names include: N,N,-alpha-trimethyl-benzeneethanamine and 632
N,N-alpha-trimethylphenethylamine); 633
(13) Synthetic cathinones. (A) Unless listed in 634
another schedule, any compound other than bupropion that is 635
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 27 (ens\tb)

structurally derived from 2-Amino-1-phenyl-1-propanone by 636
modification in any of the following ways: 637
(i) By substitution in the phenyl ring to any 638
extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide 639
substituents, whether or not further substituted in the phenyl 640
ring by one or more other univalent substituents; 641
(ii) By substitution at the 3-position with 642
an alkyl substituent; 643
(iii) By substitution at the nitrogen atom 644
with alkyl or dialkyl groups, or by inclusion of the nitrogen atom 645
in a cyclic structure. 646
(B) The compounds covered in this paragraph (10) 647
include, but are not limited to, any material, compound, mixture 648
or preparation which contains any quantity of a synthetic 649
cathinone found in any of the following compounds, whether or not 650
substituted to any extent, or any of these compounds which contain 651
any synthetic cathinone, or salts, isomers, or salts of isomers, 652
whenever the existence of such salts, isomers or salts of isomers 653
is possible, unless specifically excepted or listed in another 654
schedule: 655
(i) 4-methyl-N-ethylcathinone ("4-MEC"); 656
(ii) 4-methyl-alpha-pyrrolidinopropiophenone 657
("4-MePPP"); 658
(iii) Alpha-pyrrolidinopentiophenone 659
("α-PVP"); 660
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 28 (ens\tb)

(iv) 1-(1,3-benzodioxol-5-yl)-2- 661
(methylamino)butan-1-one ("butylone"); 662
(v) 2-(methylamino)-1-phenylpentan-1-one 663
("pentedrone"); 664
(vi) 1-(1,3-benzodioxol-5-yl)-2- 665
(methylamino)pentan-1-one ("pentylone"); 666
(vii) 4-fluoro-N-methylcathinone ("4-FMC"); 667
(viii) 3-fluoro-N-methylcathinone ("3-FMC"); 668
(ix) 1-(naphthalen-2-yl)-2- (pyrrolidin-1-yl) 669
pentan-1-one ("naphyrone"); 670
(x) Alpha-pyrrolidinobutiophenone ("α-PBP"); 671
(xi) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino) 672
-pentan-1-one (N-ethylpentylone, ephylone); 673
(14) a-PiHP 674
4-methyl-1-phenyl-2-pyrrolidin-1-yl)pentan-1-one, also known as 675
alpha-PiHP; and 676
(15) 3–MMC 677
2-methylamino)-1-3-methylphenyl)propan-1-one, also known as 678
3-methylmethcathinone. 679
SECTION 3. Section 41-29-115, Mississippi Code of 1972, is 680
amended as follows: 681
41-29-115. (a) The controlled substances listed in this 682
section, by whatever official name, common or usual name, chemical 683
name, or brand name designated, are included in Schedule II. 684
SCHEDULE II 685
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 29 (ens\tb)

(b) Substances, vegetable origin or chemical synthesis. 686
Unless specifically excepted or unless listed in other schedules, 687
any of the following substances, whether produced directly or 688
indirectly by extraction from substances of vegetable origin, or 689
independently by means of chemical synthesis, or by combination of 690
extraction and chemical synthesis: 691
(1) Opium and opiate, and any salt, compound, 692
derivative, or preparation of opium or opiate, excluding 693
apomorphine, thebaine-derived butorphanol, dextrorphan, 694
nalbuphine, naldemedine, nalmefene, naloxegol, naloxone and 695
naltrexone, but including the following: 696
(i) Codeine; 697
(ii) Dihydroetorphine; 698
(iii) Ethylmorphine; 699
(iv) Etorphine hydrochloride; 700
(v) Granulated opium; 701
(vi) Hydrocodone, whether alone or in combination 702
with any material, compound, mixture or preparation; 703
(vii) Hydromorphone; 704
(viii) Metopon; 705
(ix) Morphine; 706
(x) Opium extracts; 707
(xi) Opium fluid extracts; 708
(xii) Oripavine; 709
(xiii) Oxycodone; 710
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 30 (ens\tb)

(xiv) Oxymorphone; 711
(xv) Powdered opium; 712
(xvi) Raw opium; 713
(xvii) Thebaine; 714
(xviii) Tincture of opium; 715
(2) Any salt, compound, isomer, derivative, or 716
preparation thereof which is chemically equivalent or identical 717
with any of the substances referred to in paragraph (1), but not 718
including the isoquinoline alkaloids of opium; 719
(3) Opium poppy and poppy straw; 720
(4) Coca leaves and any salt, compound, derivative, or 721
preparation of cocaine or coca leaves, including cocaine and 722
ecgonine and any salt, compound, derivative, isomer, or 723
preparation thereof which is chemically equivalent or identical 724
with any of these substances, but not including: 725
(i) Decocainized coca leaves or extraction of coca 726
leaves, which extractions do not contain cocaine or ecgonine; or 727
(ii) Ioflupane; 728
(5) Concentrate of poppy straw (the crude extract of 729
poppy straw in either liquid, solid or powder form which contains 730
the phenanthrene alkaloids of the opium poppy). 731
(c) Opiates. Any of the following opiates, including their 732
isomers, esters, ethers, salts, and salts of isomers, whenever the 733
existence of these isomers, esters, ethers and salts is possible 734
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 31 (ens\tb)

within the specified chemical designation, dextrorphan and 735
levopropoxyphene excepted: 736
(1) Alfentanil; 737
(2) Alphaprodine; 738
(3) Anileridine; 739
(4) Bezitramide; 740
(5) Bulk dextropropoxyphene (nondosage forms); 741
(6) Carfentanil; 742
(7) Dihydrocodeine; 743
(8) Diphenoxylate; 744
(9) Fentanyl; 745
(10) Isomethadone; 746
(11) Levo-alphacetylmethadol 747
(levo-alpha-acetylmethadol, levomethadyl acetate, LAAM); 748
(12) Levomethorphan; 749
(13) Levorphanol; 750
(14) Metazocine; 751
(15) Methadone; 752
(16) Methadone-intermediate, 753
4-cyano-2-dimethylamino-4,4-diphenyl butane; 754
(17) Moramide-intermediate, 755
2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid; 756
(18) Oliceridine 757
(N-[(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6- 758
oxaspiro[4.5]decan-9-yl]ethyl})amine); 759
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 32 (ens\tb)

(19) Pethidine (meperidine); 760
(20) Pethidine-Intermediate-A, 761
4-cyano-1-methyl-4-phenylpiperidine; 762
(21) Pethidine-Intermediate-B, 763
ethyl-4-phenylpiperidine-4-carboxylate; 764
(22) Pethidine-Intermediate-C, 765
1-methyl-4-phenylpiperidine-4-carboxylic acid; 766
(23) Phenazocine; 767
(24) Piminodine; 768
(25) Racemethorphan; 769
(26) Racemorphan; 770
(27) Remifentanil; 771
(28) Sufentanil; 772
(29) Tapentadol; 773
(30) Thiafentanil, methyl 774
4-(2-methoxy-N-phenylacetamido)-1-(2-(thiophen-2-yl)ethyl) 775
piperidine-4-carboxylate). 776
(d) Stimulants. Any material, compound, mixture, or 777
preparation which contains any quantity of the following 778
substances: 779
(1) Amphetamine, its salts, optical isomers, and salts 780
of its optical isomers; 781
(2) Phenmetrazine and its salts; 782
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 33 (ens\tb)

(3) Any substance which contains any quantity of 783
methamphetamine, including its salts, isomers, and salts of 784
isomers; 785
(4) Methylphenidate and its salts; 786
(5) Lisdexamfetamine, its salts, isomers and salts of 787
isomers. 788
(e) Depressants. Unless specifically exempted or unless 789
listed in another schedule, any material, compound, mixture, or 790
preparation which contains any quantity of the following 791
substances: 792
(1) Amobarbital; 793
(2) Secobarbital; 794
(3) Pentobarbital; 795
(4) Glutethimide. 796
(f) Hallucinogenic substances. 797
(1) Dronabinol oral solution 798
[(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)]; 799
(2) Nabilone [other names include: 800
(+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a- 801
hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one] 802
(3) Ibogaine and its isomers, esters, ethers, salts, 803
and salts of isomers, whenever the existence of these isomers, 804
esters, ethers and salts is possible within the specified chemical 805
designation, except for possession, manufacturing, distribution, 806
S. B. No. 2562 *SS26/R1048.1* ~ OFFICIAL ~
26/SS26/R1048.1
PAGE 34 (ens\tb)
ST: Mississippi Veterans PTSD Ibogaine Research
Pilot Program; create.
dispensing, or administering pursuant to the program created in 807
Section 1 of this act. 808
(g) Immediate precursors. Unless specifically excepted or 809
unless listed in another schedule, any material, compound, 810
mixture, or preparation which contains any quantity of the 811
following substances: 812
(1) Amphetamine and methamphetamine immediate 813
precursor: Phenylacetone (other names include: 814
phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl 815
ketone); 816
(2) Phencyclidine immediate precursors: 817
(i) 1-phenylcyclohexylamine; 818
(ii) 1-piperidinocyclohexanecarbonitrile (PCC); 819
(3) Fentanyl immediate precursor: 820
4-anilino-N-phenethyl-4-piperidine (ANPP). 821
(h) Any material, compound, mixture or preparation which 822
contains any quantity of a Schedule II controlled substance and is 823
listed as an exempt substance in 21 CFR, Section 1308.24 or 824
1308.32, shall be exempted from the provisions of the Uniform 825
Controlled Substances Law. 826
SECTION 4. This act shall take effect and be in force from 827
and after July 1, 2026. 828